Table II.

Summary of clinical manifestations for nine patients with IMT of bladder.

Patient	Sex	Age, years	Immunohistochemistry	Operation	Other treatment	Follow-up time	Follow-up method	Prognosis
1	Female	63	CK+, Vimentin+, SMA+, CD34 (Vascular+), LCA (Stove+)	Cystoscopy		1 month	Ultrasound	No recurrence
2	Female	60	Desmin (Individual+), ALK+	Transurethral resection of bladder tumor		1 month	Ultrasound	No recurrence
3	Female	35	CK+, EMA+, ALK+, SMA (Stove+), CD30 (Minority+)	Partial cystectomy		3 months	Bladder endoscopy	No recurrence
4	Male	28	CK+, EMA+, ALK+, Vimentin+, SMA (Stove+), CD68 (Scattered+)	Partial cystectomy and pelvic lymph node dissection		7 months	CT, ultrasound, Magnetic resonance imaging	No recurrence
5	Female	14	AE1/AE3 (Weak+), CD34 (Vascular+), ALK+, SMA+, Desmin (Stove+)	Transurethral resection of bladder tumor	Bladder perfusion therapy	2 months	Bladder endoscopy	No recurrence
6	Male	35	SMA (Stove+), Desmin (Stove+), ALK (Stove+)	Transurethral resection of bladder tumor plus partial cystectomy		19 months	Bladder endoscopy, CT, ultrasound	No recurrence
7	Female	7	ALK+, AE1/AE3 (Partial+), SMA (Partial+), Desmin (Partial+)	Bladder tumor excision		2 months	Ultrasound	No recurrence
8	Male	75	CK7+, CK20 (Epithelial+), SMA+, ERG (Partial+), GATA-3+	Rod-shaped prostatic dilatation plus electrotomy of bladder neck and mouth		1 month	Magnetic resonance imaging	No recurrence
9	Male	47	AE1/AE3+, CD117 (Stove+), Vimentin+, CD99+, P53 (60%)	Laparoscopic radical cystectomy and in situ cystectomy		4 months	CT	No recurrence

CT, computed tomography; ALK, anaplastic lymphoma kinase-1.